Evergreen Therapeutics, Inc.

This early-stage trial tests a new drug called EG-101 in 24 healthy women to make sure it is safe before trying it in pregnant women with severe pre-eclampsia, a dangerous condition that causes high blood pressure and organ damage. The study will measure how the drug moves throug…

This study tests an experimental pill (EG-301) taken daily for at least 6 months in 90 people with dry age-related macular degeneration (AMD) and geographic atrophy. Participants are randomly assigned to receive either standard AREDS2 supplements alone or AREDS2 plus EG-301. The …

This Phase 3 trial tests whether adding the drug EG-007 to a standard combination of lenvatinib and pembrolizumab helps people with advanced or recurrent endometrial cancer live longer without their cancer growing. About 450 participants will be randomly assigned to receive eithe…

This phase 2 trial tests whether adding a repurposed drug called EG-007 to the standard combination of lenvatinib and pembrolizumab is safe for people with advanced or recurrent endometrial cancer. The study will enroll 28 adults whose cancer has progressed after platinum chemoth…